<DOC>
	<DOCNO>NCT02381652</DOCNO>
	<brief_summary>The objective study evaluate safety repeat injection Cingal® subject Osteoarthritis ( OA ) knee participate Cingal 13-01 . This do examination incidence adverse event physical examination knee .</brief_summary>
	<brief_title>Repeat Injection Cingal® Osteoarthritis Knee</brief_title>
	<detailed_description>The Cingal 13-02 study follow-on study recently complete clinical trial Cingal 13-01 . Cingal 13-01 multi-center , randomize , double-blind , Phase III study enrol 368 subject 30 site Canada Europe . The Cingal 13-01 study objective ass safety effectiveness single injection Cingal® relief joint pain symptom patient OA knee . The study three arm : Cingal® investigational arm , active comparator arm ( Monovisc® ) control arm ( saline ) . Cingal 13-02 design evaluate safety open-label injection Cingal® subject receive study injection Cingal 13-01 trial .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>1 . Subject complete Cingal 1301 interested participate followon study 2 . Subject must willing abstain intraarticular surgical treatment index knee duration study 3 . Subject willing discontinue analgesic except acetaminophen/paracetamol duration study 4 . Subject willing use acetaminophen/paracetamol ( maximum 4.0 gram per day per package insert ) treatment joint pain duration study . At least twentyfour hour prior injection followup visit , subject willing discontinue use acetaminophen/paracetamol 5 . Subject able understand comply requirement study voluntarily provide consent 1 . Subject receive intraarticular injection underwent surgical procedure index knee since study injection Cingal 1301 2 . Subject take medication time consent could interfere treatment procedure , heal and/or assessment . This include limited oral injectable anticoagulant treatment , antiaggregant platelet treatment opioid analgesic . Low dose aspirin use cardiovascular protection allow stable regimen maintain duration study . 3 . Subjects oral , intramuscular , intravenous , rectal suppository topical ( excluded index knee ) corticosteroid within 30 day sign ICF exclude . Topical corticosteroid use site index knee allow . 4 . Subject contraindication IA injection , aspiration index knee , corticosteroid , hyaluronan , acetaminophen/paracetamol . 5 . Subject pregnant breastfeed woman child bear potential refuse use effective contraception course study . 6 . Subject participate research study Cingal 1301 within 60 day consent .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>